Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.
Lupus
; 25(8): 823-9, 2016 Jul.
Article
en En
| MEDLINE
| ID: mdl-27252258
ABSTRACT
Systemic lupus erythematosus (SLE) can be a mysterious disease, presenting with extremely divergent clinical phenotypes. Already, biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and they hold the key to personalized medicine in SLE. We summarize the clinical information that can only be supplied by autoantibodies, complement components and interferon biomarkers in this diverse disease.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Autoanticuerpos
/
Proteínas del Sistema Complemento
/
Interferón Tipo I
/
Lupus Eritematoso Sistémico
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Lupus
Asunto de la revista:
REUMATOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Alemania